UK Markets open in 4 hrs 47 mins

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
141.28+3.83 (+2.79%)
At close: 04:00PM EDT
141.28 0.00 (0.00%)
After hours: 04:11PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3169.98
52-week low 3125.36
50-day moving average 3147.10
200-day moving average 3149.02

Share statistics

Avg vol (3-month) 3526.99k
Avg vol (10-day) 3506.17k
Shares outstanding 562.97M
Implied shares outstanding 6N/A
Float 861.22M
% held by insiders 12.51%
% held by institutions 196.00%
Shares short (30 Jan 2023) 42.58M
Short ratio (30 Jan 2023) 45.65
Short % of float (30 Jan 2023) 44.69%
Short % of shares outstanding (30 Jan 2023) 44.10%
Shares short (prior month 29 Dec 2022) 42.7M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -0.52%
Operating margin (ttm)27.02%

Management effectiveness

Return on assets (ttm)5.30%
Return on equity (ttm)-0.56%

Income statement

Revenue (ttm)3.58B
Revenue per share (ttm)57.66
Quarterly revenue growth (yoy)12.20%
Gross profit (ttm)2.88B
Net income avi to common (ttm)-18.69M
Diluted EPS (ttm)4.22
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)899.36M
Total cash per share (mrq)14.28
Total debt (mrq)5.81B
Total debt/equity (mrq)211.81
Current ratio (mrq)3.16
Book value per share (mrq)65.15

Cash flow statement

Operating cash flow (ttm)1.11B
Levered free cash flow (ttm)1.54B